Cargando…
Cross-Presenting XCR1(+) Dendritic Cells as Targets for Cancer Immunotherapy
The use of dendritic cells (DCs) to generate effective anti-tumor T cell immunity has garnered much attention over the last thirty-plus years. Despite this, limited clinical benefit has been demonstrated thus far. There has been a revival of interest in DC-based treatment strategies following the re...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140519/ https://www.ncbi.nlm.nih.gov/pubmed/32121071 http://dx.doi.org/10.3390/cells9030565 |